IOVA Stock Analysis: Iovance Biotherapeutics | NASDAQ

Cell Therapy, Immunotherapy, Oncology, Interleukin

Total Rating 45

Safety 35

Buy Signal 1.37

Biotechnology
Industry Rotation: +6.7

Market Cap: 6.38B
Avg Turnover: 169M

Risk 3d forecast

Volatility90.5%

VaR 5^th Pctl13.0%

VaR vs Median-11.4%

Reward TTM

Sharpe Ratio2.28

Rel. Str. IBD100

Rel. Str. Peer Group99.3 pctl

Character TTM

Beta0.989

Beta Downside1.529

Hurst Exponent0.476

Choppyness33.6%

Drawdowns 3y

Max DD90.50%

CAGR/Max DD0.63

CAGR/Mean DD0.98

EPS (Earnings per Share)

Last SUE: 1.29
Qual. Beats: 1

Revenue

Rev. CAGR: 900.07%
Rev. Trend: 88.0%

Last SUE: 0.89
Qual. Beats: 1

Warnings

Strong Share Dilution

Altman Z'' In Financial Distress Zone

Tailwinds

Supp Ema20

Rs Leader

Idiosyncratic Leader

Confidence

Seasonality 11.7 years of data

Jan -2.0% 8

Feb +1.1% 5

Mar -4.1% 51

Apr -0.3% 16

May -3.8% 8

Jun +15.9% 20

Jul +3.9% 33

Aug +3.8% 8

Sep -4.0% 18

Oct +0.6% 2

Nov +2.4% 21

Dec +6.5% 30

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: IOVA Iovance Biotherapeutics

Iovance Biotherapeutics (NASDAQ: IOVA) is a U.S.-based, commercial-stage biopharmaceutical company headquartered in San Carlos, California, focused on developing and commercializing autologous cell therapies for solid tumor cancers. Its lead product, Amtagvi, is an individualized T cell therapy approved for adult patients with previously treated advanced or metastatic melanoma, and the company also markets Proleukin, an interleukin-2 product indicated for metastatic melanoma and metastatic renal cell carcinoma.

The companys pipeline is built around its tumor infiltrating lymphocyte (TIL) platform and includes lifileucel in development across multiple solid tumor indications such as cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC), alongside next-generation candidates like LN-145 Gen 3, IOV-4001, IOV-3001, and the hematology-focused IOV-2001. Iovance supports this work through collaborations with the National Institutes of Health, the National Cancer Institute, Cellectis, Novartis Pharma, and Boehringer Ingelheim.

Iovance was incorporated in 2007 (originally as Lion Biotechnologies, renamed in June 2017), has been publicly traded since its 2010 IPO, and operates within the biotechnology sub-industry of health care. As a cell therapy developer, its business model centers on personalized, autologous manufacturing-where each dose is produced from a patients own tumor-derived T cells-which typically involves complex, centralized production logistics and reimbursement tied to clinical outcomes rather than traditional high-volume pharmaceutical distribution.

Headlines to Watch Out For

Amtagvi launch drives initial cell therapy revenue
Cash burn and dilution risk from ongoing operating losses
Pipeline expansion into NSCLC and cervical cancer indications

Piotroski VR-10 (Strict) 2.0

Net Income: -289.5m TTM > 0 and > 6% of Revenue
FCF/TA: -0.32 > 0.02 and ΔFCF/TA 3.28 > 1.0
NWC/Revenue: 110.0% < 20% (prev 121.5%; Δ -11.47% < -1%)
CFO/TA -0.29 > 3% & CFO -264.2m > Net Income -289.5m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 4.35 > 1.5 & < 3
Outstanding Shares: last quarter (450.2m) vs 12m ago 34.58% < -2%
Gross Margin: 48.40% > 18% (prev 26.73%; Δ 21.67% > 0.5%)
Asset Turnover: 35.65% > 50% (prev 26.62%; Δ 9.04% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM)

Altman Z'' -5.65

A: 0.39 (Total Current Assets 464.3m - Total Current Liabilities 106.8m) / Total Assets 915.5m
B: -3.17 (Retained Earnings -2.90b / Total Assets 915.5m)
C: -0.32 (EBIT TTM -296.2m / Avg Total Assets 911.5m)
D: 4.10 (Book Value of Equity 736.0m / Total Liabilities 179.5m)
Altman-Z'' = -5.65 = D

Beneish M -3.04

DSRI: 1.27 (Receivables 102.1m/59.9m, Revenue 325.0m/241.5m)
GMI: 0.55 (GM 26.73% / 48.40%)
AQI: 0.88 (AQ_t 0.30 / AQ_t-1 0.34)
SGI: 1.35 (Revenue 325.0m / 241.5m)
TATA: -0.03 (NI -289.5m - CFO -264.2m) / TA 915.5m)
Beneish M = -3.04 (Cap -4..+1) = AA

What is the price of IOVA shares?

As of October 29, 2026, the stock is trading at USD 14.81 with a total of 8,743,893 shares traded. Over the past week, the price has changed by +1.30%, over one month by +34.76%, over three months by +215.11% and over the past year by +576.26%.

Current recommended Stop Loss: 13.70 (which is 7.5% or 1.2 ATR below the current price).

Is IOVA a buy, sell or hold?

Iovance Biotherapeutics has received a consensus analysts rating of 4.40. Therefore, it is recommended to buy IOVA.

StrongBuy: 6
Buy: 2
Hold: 2
Sell: 0
StrongSell: 0

What are the forecasts/targets for the IOVA price?

Analysts Target Price	14.4	-2.8%

Iovance Biotherapeutics (IOVA) - Fundamental Data Overview as of 27 October 2026

Market Cap USD = 6.38b (6.38b USD * 1.0 USD.USD)
P/S = 19.6399
P/B = 6.6729
Revenue TTM = 325.0m USD
EBIT TTM = -296.2m USD
EBITDA TTM = -251.2m USD
Long Term Debt = 43.3m USD (estimated: total debt 46.0m - short term 2.67m)
Short Term Debt = 2.67m USD (from shortTermDebt, last quarter)
Debt = 46.0m USD (from shortLongTermDebtTotal, last quarter) (leases 46.0m already included)
Net Debt = -251.7m USD (calculated: Debt 46.0m - CCE 297.7m)
Enterprise Value = 6.13b USD (6.38b + Debt 46.0m - CCE 297.7m)
Interest Coverage Ratio = unknown (Ebit TTM -296.2m / Interest Expense TTM 0.0)
EV/FCF = -20.68x (Enterprise Value 6.13b / FCF TTM -296.4m)
FCF Yield = -4.83% (FCF TTM -296.4m / Enterprise Value 6.13b)
FCF Margin = -91.21% (FCF TTM -296.4m / Revenue TTM 325.0m)
Net Margin = -89.09% (Net Income TTM -289.5m / Revenue TTM 325.0m)
Gross Margin = 48.40% ((Revenue TTM 325.0m - Cost of Revenue TTM 167.7m) / Revenue TTM)
Gross Margin QoQ = 56.10% (prev 40.50%)
Tobins Q-Ratio = 6.70 (Enterprise Value 6.13b / Total Assets 915.5m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 46.0m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -234.0m (EBIT -296.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.35 (Total Current Assets 464.3m / Total Current Liabilities 106.8m)
Debt / Equity = 0.06 (Debt 46.0m / totalStockholderEquity, last quarter 736.0m)
Debt / EBITDA = 1.00 (negative EBITDA) (Net Debt -251.7m / EBITDA -251.2m)
Debt / FCF = 0.85 (negative FCF - burning cash) (Net Debt -251.7m / FCF TTM -296.4m)
Total Stockholder Equity = 714.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -31.76% (Net Income -289.5m / Total Assets 915.5m)
RoE = -40.51% (Net Income TTM -289.5m / Total Stockholder Equity 714.7m)
RoCE = -39.07% (EBIT -296.2m / Capital Employed (Equity 714.7m + L.T.Debt 43.3m))
RoIC = -29.43% (negative operating profit) (NOPAT -234.0m / Invested Capital 795.1m)
WACC = 8.90% (E(6.38b)/V(6.43b) * Re(8.96%) + D(46.0m)/V(6.43b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 8.96% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 97.85 | Cagr: 26.30%
[DCF] Fair Price = unknown (Cash Flow -296.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.29 | # QB: 1
Revenue Correlation: 87.98 | Revenue CAGR: 900.1% | SUE: 0.89 | # QB: 1
EPS current Quarter (2026-09-30): EPS=-0.09 | Chg30d=+10.77% | Revisions=+40% | Analysts=8
EPS current Year (2026-12-31): EPS=-0.45 | Chg30d=+9.02% | Revisions=+62% | GrowthEPS=+58.6% | GrowthRev=+56.6%
EPS next Year (2027-12-31): EPS=-0.20 | Chg30d=+31.85% | Revisions=+62% | GrowthEPS=+56.6% | GrowthRev=+43.8%
[Analyst] Revisions Ratio: +80% (up=12, down=0)